{"protocolSection": {"identificationModule": {"nctId": "NCT06292286", "orgStudyIdInfo": {"id": "UW 22-704"}, "organization": {"fullName": "The University of Hong Kong", "class": "OTHER"}, "briefTitle": "Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer", "officialTitle": "Secondary Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer Patients - a Pilot Study", "acronym": "SCENIC"}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Dr. Ka-Yu Tse", "investigatorTitle": "Clinical Associate Professor", "investigatorAffiliation": "The University of Hong Kong"}, "leadSponsor": {"name": "The University of Hong Kong", "class": "OTHER"}}, "descriptionModule": {"briefSummary": "About 80% of advanced ovarian cancer patients recurred in 2-3 years. Secondary cytoreduction benefits selected patients who have high chance of complete resection. Whether secondary interval surgery can be used at recurrence is not known.", "detailedDescription": "Our study aims to evaluate the complete resection rate at interval cytoreductive surgery for recurrent ovarian cancer patients, and to determine the safety and survival outcomes of this approach."}, "conditionsModule": {"conditions": ["Recurrent Ovarian Carcinoma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": "Neoadjuvant carboplatin and paclitaxel followed by cytoreductive surgery", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 18, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Chemotherapy and surgery arm", "type": "EXPERIMENTAL", "description": "Patients receive platinum-based chemotherapy with or without bevacizumab, and then undergo cytoreductive operation, for the first recurrence of EOC.", "interventionNames": ["Procedure: Carboplatin or cisplatin", "Drug: Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar", "Drug: Bevacizumab or biosimilar", "Procedure: Cytoreductive surgery"]}], "interventions": [{"type": "PROCEDURE", "name": "Carboplatin or cisplatin", "description": "Carboplatin of cisplatin for 3-6 cycles", "armGroupLabels": ["Chemotherapy and surgery arm"], "otherNames": ["Paraplatin or Platinol"]}, {"type": "DRUG", "name": "Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar", "description": "Paclitaxel, gemcitabine or liposomal doxorubicin, for 3-6 cycles", "armGroupLabels": ["Chemotherapy and surgery arm"], "otherNames": ["Taxol, Gemzar, Caelyx"]}, {"type": "DRUG", "name": "Bevacizumab or biosimilar", "description": "Optional", "armGroupLabels": ["Chemotherapy and surgery arm"], "otherNames": ["Avastin or mvasi"]}, {"type": "PROCEDURE", "name": "Cytoreductive surgery", "description": "Cytoreductive surgery after chemotherapy", "armGroupLabels": ["Chemotherapy and surgery arm"]}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically diagnosed EOC, fallopian tube or primary peritoneal carcinoma\n* \\>= 3 cycles of platinum-based chemotherapy, with or without bevacizumab and / or PARPi, at primary setting\n* Platinum-free interval should be \\>=6 months from the last dose of platinum-based chemotherapy\n* Upfront SCR not feasible\n* Patients should have Eastern Cooperative Oncology Group (ECOG) performance score 0 to 2 within 28 days prior to recruitment.\n* Patients must have adequate bone marrow, renal, hepatic and neurological function within 28 days prior to the start of treatment.\n\nExclusion Criteria:\n\n* Non-epithelial or borderline tumors are excluded\n* Patients who have with concurrent malignancy within five years (except for basal or squamous cell skin cancer, in-situ breast cancer, stage 1a grade 1-2 endometrioid endometrial carcinoma without lymphovascular invasion) are excluded.\n* Patients using more than one line of chemotherapy are excluded.\n* Patients who have platinum-resistant or refractory recurrence are excluded.\n* Patients having second relapse or beyond are excluded.\n* Patients who have contraindications to operation, e.g., unresolved thrombocytopenia, bowel obstruction in the last 4 weeks prior to enrolment", "healthyVolunteers": false, "sex": "FEMALE", "genderBased": true, "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Lesley Lau", "role": "CONTACT", "phone": "852-22554265", "email": "lsk382@hku.hk"}], "overallOfficials": [{"name": "Ka Yu Tse", "affiliation": "The University of Hong Kong", "role": "PRINCIPAL_INVESTIGATOR"}]}}, "hasResults": false}